To test this possibility, we compared the differences of immune cells in CCL2-low and CCL2-high GBM groups, and also analyzed the correlation of CCL2 with a variety of immune cells through TIMER2.0 algorithm [16]. The gene discussed is CCL2; the disease is glioblastoma.